SG Americas Securities LLC Cuts Stake in IDEXX Laboratories, Inc. $IDXX

SG Americas Securities LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,425 shares of the company’s stock after selling 1,608 shares during the period. SG Americas Securities LLC owned 0.05% of IDEXX Laboratories worth $29,378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Virtus Advisers LLC purchased a new position in IDEXX Laboratories during the third quarter valued at $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories in the 4th quarter worth $29,000. J.Safra Asset Management Corp bought a new position in shares of IDEXX Laboratories during the 3rd quarter valued at about $31,000. Armstrong Advisory Group Inc. boosted its holdings in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Finally, Salomon & Ludwin LLC purchased a new position in shares of IDEXX Laboratories during the third quarter valued at about $35,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research analyst reports. Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Piper Sandler lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. BTIG Research cut their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Finally, UBS Group reduced their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,957 shares of company stock worth $29,862,109 in the last ninety days. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Down 0.4%

IDXX opened at $573.29 on Friday. The stock has a 50-day moving average of $634.46 and a 200 day moving average of $662.53. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The firm has a market cap of $45.59 billion, a P/E ratio of 43.86, a P/E/G ratio of 3.50 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.